Trichomoniasis (overview)A59.9

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Infection with trichomonads (multi-flagellate flagellates). The pathogen is almost always transmitted via sexual contact.

PathogenThis section has been translated automatically.

For humans 3 species are pathogenic:

Trichomonas vaginalis: infection of the mucous membrane surfaces in the urogenital tract (worldwide most common sexually transmitted disease; the pathogen can survive in a warm and humid environment for 24 hours. Transmission through infected objects is possible).

Trichomonas tenax: infection of the oral mucosa (especially gingivitis)

Pentatrichomonas hominis: infection of the intestinal mucosa

ClassificationThis section has been translated automatically.

Occurrence/EpidemiologyThis section has been translated automatically.

Trichomonas vaginalis infections occur worldwide. They are among the most common STI pathogens.

Prevalence (worldwide): 250 million infected persons per year. In some tropical countries, trichomonads are the most common pathogens of genital infections.

The prevalence in women is reported as 3%-48%, depending on the population studied. 20% of the women between the ages of 16 and 35 years were infected with trichomonas at least once (Hearn LE et al. 2015).

About 70% of women with gonorrheic infection are co-infected by trichomonads.

In men with non-gonorrheic urethritis (NGU), trichomonads can be detected in 15%.

ManifestationThis section has been translated automatically.

Affected are mainly adults. Infections in newborns are rare (transmission of the pathogens from mother to child at birth).

External therapyThis section has been translated automatically.

Support of the system therapy: Clotrimazole (e.g. Canesten vaginal tablets) and other imidazole derivatives like miconazole (e.g. Daktar cream), Econazole (e.g. Epi-Pevaryl cream) or Econazole vaginal suppositories (e.g. Gyno-Pevaryl 6 Ovula).

Alternative to systemic therapy: Recent studies show that in trichomondanecolpitis an intravaginal combination of metronidazole and miconazole is an effective alternative to systemic therapy.

Notice! Co-treatment of the sexual partner, even in the absence of symptoms (ping-pong effect)!

Internal therapyThis section has been translated automatically.

Agent of choice is Metronidazole (e.g. Clont, Arilin) 1.5-2 g p.o. as ED (healing rate 90%), alternatively 2 times/day 400 mg over 5-7 days (healing rate 95%).

In HIV-positive women a 7-day regime with 2x500mg metronidazole p.o. for 7 days is recommended.

In HIV-positive men, a single dose of 2.0g metronidazole p.o. is sufficient.

Notice! Take Metronidazole before meals on an empty stomach, otherwise delayed absorption and reduced blood levels may occur!

In case of therapy failure repeat administration of 400 mg metronidazole 2 times/day for 5-7 days. In the absence of success, increase the metronidazole dose to 2 g p.o. once/day for 3-5 days. Also effective are tinidazole (e.g. Simplotan Filmtbl.) 2 g p.o. as single dose or nimorazole (e.g. Esclama Filmtbl.) in a dose of 2 g p.o. as single dose.

Metronidazole may also be used during pregnancy.

NaturopathyThis section has been translated automatically.

Smaller positive clinical group results are available with perorally applied extracts of Commiphora molmol (see myrrh below).

LiteratureThis section has been translated automatically.

  1. El-Sherbini GT et al.(2009) Efficacy of two plant extracts against vaginal trichomoniasis. J Egypt Soc Parasitol 39:47-58.
  2. Hearn LE et al (2015) Correlates of Trichomonas vaginalis Among Middle Age and Older Adults Who Use Drugs. Subst Use Misuse. 50:1501-1509.
  3. Kissinger P(2015)Trichomonas vaginalis: a review of epidemiologic, clinical and treatment issues. BMC Infect Dis 15:307
  4. Korzeniewski K et al (2015) Travel-related sexually transmitted infections. Int Marit Health 66:238-246.
  5. Momeni Z et al (2015) Molecular typing of the actin gene of Trichomonas vaginalis isolates by PCR-RFLP in Iran. Exp Parasitol 159:259-263.

Authors

Last updated on: 29.10.2020